
- The French partner VFP Therapies has developed innovative chemical entities which are improved prodrugs called Bioprecursors: they have the ability to easily go through the BBB and selectively act on specific receptors to induce therapeutic effects.
- Alzex currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineer and research institute.
- “Spending on care for people alive in the U.S. right now who will develop the affliction is projected to cost $47 trillion.“ – Another Alzheimer’s Drug Fails as Lilly, Astra Halt Tests, Bloomberg.
- Currently conducting preclinical trials and expect to enter phase 1 in one to two years
- Potential licensing arrangement opportunities for big pharmaceutical companies
- Has potential to be applied to other brain diseases such as Parkinson’s, dementia, schizophrenia, cancer, etc.